G-Rex500M Bioreactors for Cell Therapy Manufacturing

The National Institutes of Health (NIH) intends to award a sole-source contract to Wilson Wolf Manufacturing LLC for the purchase of seven cases of G-Rex500M-CS bioreactors to support the manufacture of cell-based therapies for patients enrolled in NIH clinical trials. The bioreactors are required to maintain manufacturing consistency, comply with approved production protocols, and ensure uninterrupted patient care. Interested parties believing they can satisfy this requirement may submit a capability statement. The key aspects of this opportunity include the provision of validated G-Rex500M bioreactors, compliance with FDA-regulated manufacturing processes, and the potential for schedule delays and increased costs if an alternative product is used. • The contract is for a firm-fixed-price purchase order. • The product required is the G-Rex500M-CS bioreactor. • The quantity required is seven cases. • The place of performance is the National Institutes of Health, Clinical Center, in Bethesda, MD. • The acquisition is being conducted pursuant to FAR 13.106-1(b)(1), Soliciting from a Single Source.